{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hereditary+Retinal+Dystrophy&page=2",
    "query": {
      "condition": "Hereditary Retinal Dystrophy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hereditary+Retinal+Dystrophy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T01:36:53.147Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05417126",
      "title": "Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stargardt Disease"
      ],
      "interventions": [
        {
          "name": "Gene Therapy-vMCO-010",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Nanoscope Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2022-07-05",
      "completion_date": "2023-09-28",
      "has_results": false,
      "last_update_posted_date": "2023-11-09",
      "last_synced_at": "2026-06-11T01:36:53.147Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • McAllen, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "McAllen",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05417126"
    },
    {
      "nct_id": "NCT02909985",
      "title": "Visual Activity Evoked by Infrared in Humans After Dark Adaptation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Age Related Macular Degeneration",
        "Retinitis Pigmentosa",
        "Congenital Stationary Night Blindness",
        "Colorblindness"
      ],
      "interventions": [
        {
          "name": "Tungsten halogen light with narrow bandpass filters",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of New Mexico",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2015-09",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2024-12-13",
      "last_synced_at": "2026-06-11T01:36:53.147Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02909985"
    },
    {
      "nct_id": "NCT00000116",
      "title": "Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Retinitis Pigmentosa"
      ],
      "interventions": [
        {
          "name": "Vitamin A",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Docosahexaenoic acid",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Control fatty acid",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Carol Weigel DiFranco",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 221,
      "start_date": "1996-05",
      "completion_date": "2002-09",
      "has_results": false,
      "last_update_posted_date": "2023-03-08",
      "last_synced_at": "2026-06-11T01:36:53.147Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000116"
    },
    {
      "nct_id": "NCT06627179",
      "title": "Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Retinitis Pigmentosa (RP)",
        "Usher Syndrome Type 2",
        "Deaf Blind",
        "Retinal Disease",
        "Eye Diseases, Hereditary",
        "Eye Disorders Congenital",
        "Vision Disorders"
      ],
      "interventions": [
        {
          "name": "Intravitreal Injection of Ultevursen",
          "type": "DRUG"
        },
        {
          "name": "No intervention, will not receive any active study intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Laboratoires Thea",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Years and older"
      },
      "enrollment_count": 81,
      "start_date": "2024-12-11",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-06-11T01:36:53.147Z",
      "location_count": 11,
      "location_summary": "San Francisco, California • Miami, Florida • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06627179"
    },
    {
      "nct_id": "NCT05429736",
      "title": "Activating Spinal Circuits to Improve Walking, Balance, Strength, and Reduce Spasticity",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Incomplete Spinal Cord Injury",
        "Spasticity, Muscle"
      ],
      "interventions": [
        {
          "name": "Motor Skill Training (MST)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Transcutaneous Spinal Stimulation (TSS)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DEVICE"
      ],
      "sponsor": "Shepherd Center, Atlanta GA",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 28,
      "start_date": "2022-03-01",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-06-11T01:36:53.147Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05429736"
    },
    {
      "nct_id": "NCT01233609",
      "title": "Trial of Oral Valproic Acid for Retinitis Pigmentosa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Retinitis Pigmentosa"
      ],
      "interventions": [
        {
          "name": "Valproic Acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Foundation Fighting Blindness",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2010-11",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2017-12-02",
      "last_synced_at": "2026-06-11T01:36:53.147Z",
      "location_count": 6,
      "location_summary": "Miami, Florida • Ann Arbor, Michigan • Portland, Oregon + 3 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01233609"
    },
    {
      "nct_id": "NCT02065011",
      "title": "A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Usher's Syndrome"
      ],
      "interventions": [
        {
          "name": "Blood draw for the laboratory assessment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2013-09-12",
      "completion_date": "2031-06-13",
      "has_results": false,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-06-11T01:36:53.147Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02065011"
    },
    {
      "nct_id": "NCT00470977",
      "title": "Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Coats' Disease",
        "Idiopathic Retinal Telangiectasia",
        "Retinal Angiomatous Proliferation",
        "Polypoidal Choroidal Vasculopathy",
        "Pseudoxanthoma Elasticum",
        "Pathological Myopia",
        "Multi-focal Choroiditis",
        "Rubeosis Iridis",
        "Von Hippel Lindau Disease",
        "BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)"
      ],
      "interventions": [
        {
          "name": "ranibizumab injection (0.5 mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Manhattan Eye, Ear & Throat Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2007-05",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2012-10-25",
      "last_synced_at": "2026-06-11T01:36:53.147Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00470977"
    },
    {
      "nct_id": "NCT05203939",
      "title": "Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Retinitis Pigmentosa",
        "Leber Congenital Amaurosis"
      ],
      "interventions": [
        {
          "name": "OCU400 Low Dose",
          "type": "DRUG"
        },
        {
          "name": "OCU400 Med Dose",
          "type": "DRUG"
        },
        {
          "name": "OCU400 High Dose",
          "type": "DRUG"
        },
        {
          "name": "OCU400 Second Eye Dosing",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ocugen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2022-01-24",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2025-08-06",
      "last_synced_at": "2026-06-11T01:36:53.147Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Miami, Florida + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05203939"
    },
    {
      "nct_id": "NCT01860092",
      "title": "New Enrollment Post-Approval Study of the Argus® II Retinal Prosthesis System",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Retinitis Pigmentosa"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Second Sight Medical Products",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "25 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2014-01",
      "completion_date": "2020-03",
      "has_results": false,
      "last_update_posted_date": "2021-12-23",
      "last_synced_at": "2026-06-11T01:36:53.147Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • Denver, Colorado • Miami, Florida + 13 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01860092"
    }
  ]
}